This work is licensed under the Creative Commons Attribution 4.0 International License.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JCF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC scientific document group. Eur Heart J. 2016; 37:2129–200.PonikowskiPVoorsAAAnkerSDBuenoHClelandJCFCoatsAJSFalkVGonzalez-JuanateyJRHarjolaVPJankowskaEAJessupMLindeCNihoyannopoulosPParissisJTPieskeBRileyJPRosanoGMCRuilopeLMRuschitzkaFRuttenFHvan der MeerPESC scientific document groupEur Heart J201637212920010.1093/eurheartj/ehw12827206819Search in Google Scholar
Bieske P, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancelloti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowsky P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitza F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). 2019; 40:3297–317.BieskePTschopeCde BoerRAFraserAGAnkerSDDonalEEdelmannFFuMGuazziMLamCSPLancellotiPMelenovskyVMorrisDANagelEPieske-KraigherEPonikowskyPSolomonSDVasanRSRuttenFHVoorsAARuschitzaFPaulusWJSeferovicPFilippatosGHow to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)201940329731710.1093/eurheartj/ehz64131504452Search in Google Scholar
Triposkiadis F, Butler J, Abboud FM, Armstrong PW, Adamopoulos S, Atherton JJ, Backs J, BauerSachs J, Burkhoff D, Bonow RO, Chopra VK, de Boer RA, de Windt L, Hamdani N, Hasenfuss G, Heymans S, Hulot JS, Konstam M, Lee RT, Linke WA, Lunde IG, Lyon AR, Maack C, Mann DL, Mebazaa A, Mentz RJ, Nihoyannopoulos P, Papp Z, Parisiss J, Pedrazzini T, Rosano G, Rouleau J, Seferovic PM, Shah AM, Starling RC, Tocchetti CG, Trochu JN, Thum T, Zannad F, Brutsaert DL, Segers VF, De Keulenaer GW. The continuous heart failure spectrum: moving beyond an ejection fraction classification. Eur Heart J. 2019; 40:2155–63.TriposkiadisFButlerJAbboudFMArmstrongPWAdamopoulosSAthertonJJBacksJBauerSachsJBurkhoffDBonowROChopraVKde BoerRAde WindtLHamdaniNHasenfussGHeymansSHulotJSKonstamMLeeRTLinkeWALundeIGLyonARMaackCMannDLMebazaaAMentzRJNihoyannopoulosPPappZParisissJPedrazziniTRosanoGRouleauJSeferovicPMShahAMStarlingRCTocchettiCGTrochuJNThumTZannadFBrutsaertDLSegersVFDe KeulenaerGWThe continuous heart failure spectrum: moving beyond an ejection fraction classificationEur Heart J.20194021556310.1093/eurheartj/ehz158796312930957868Search in Google Scholar
Ueda M, Horibata Y, Shono M, Misumi Y, Oshima T, Su Y, Tasaki M, Shinriki S, Kawahara S, Jono H, Obayashi K, Ogawa H, Ando Y. Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study. Mod Pathol 2011; 24:1533–44.UedaMHoribataYShonoMMisumiYOshimaTSuYTasakiMShinrikiSKawaharaSJonoHObayashiKOgawaHAndoYClinicopathological features of senile systemic amyloidosis: an ante- and post-mortem studyMod Pathol20112415334410.1038/modpathol.2011.11721822203Search in Google Scholar
Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, Haro Del-Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015; 36:2585–94.Gonzalez-LopezEGallego-DelgadoMGuzzo-MerelloGHaro Del-MoralFJCobo-MarcosMRoblesCBornsteinBSalasCLara-PezziEAlonso-PulponLGarcia-PaviaPWild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fractionEur Heart J.20153625859410.1093/eurheartj/ehv33826224076Search in Google Scholar
Scully PR, Treibel TA, Fontana M, Lloyd G, Mullen M, Pugliese F, Hartman N, Hawkins PN, Menezes LJ, Moon JC. Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement. J Am Coll Cardiol. 2018; 71:463–4.ScullyPRTreibelTAFontanaMLloydGMullenMPuglieseFHartmanNHawkinsPNMenezesLJMoonJCPrevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacementJ Am Coll Cardiol.201871463410.1016/j.jacc.2017.11.037578029729389364Search in Google Scholar
Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR, Roberts N, Hutt DF, Rowczenio DM, Whelan CJ, Ashworth MA, Gillmore JD, Hawkins PN, Moon JC. Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging. 2016;9:e005066TreibelTAFontanaMGilbertsonJACastellettiSWhiteSKScullyPRRobertsNHuttDFRowczenioDMWhelanCJAshworthMAGillmoreJDHawkinsPNMoonJCOccult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and prognosis in patients undergoing surgical aortic valve replacementCirc Cardiovasc Imaging20169e00506610.1161/CIRCIMAGING.116.00506627511979Search in Google Scholar
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021; 42:1554–68.Garcia-PaviaPRapezziCAdlerYAradMBassoCBrucatoABurazorICaforioALPDamyTErikssonUFontanaMGillmoreJDGonzalez-LopezEGroganMHeymansSImazioMKindermannIKristenAVMaurerMSMerliniGPantazisAPankuweitSRigopoulosAGLinhartADiagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial DiseasesEur J Heart Fail.20214215546810.1093/eurheartj/ehab072806005633825853Search in Google Scholar
Bennani Smires Y, Victor G, Ribes D, Berry M, Cognet T, Mejean S, Huart A, Roussel M, Petermann A, Roncalli J, Carrie D, Rousseau H, Berry I, Chauveau D, Galinier M, Lairez O. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy. Int J Card Imaging. 2016; 32:1403–13.Bennani SmiresYVictorGRibesDBerryMCognetTMejeanSHuartARousselMPetermannARoncalliJCarrieDRousseauHBerryIChauveauDGalinierMLairezOPilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathyInt J Card Imaging.20163214031310.1007/s10554-016-0915-z27240600Search in Google Scholar
Tuzovic M, Yang EH, Baas AS, Depasquale EC, Deng MC, Cruz D, Vorobiof G. Cardiac amyloidosis: diagnosis and treatment strategies. Curr Oncol Rep 2017; 19:46.TuzovicMYangEHBaasASDepasqualeECDengMCCruzDVorobiofGCardiac amyloidosis: diagnosis and treatment strategiesCurr Oncol Rep2017194610.1007/s11912-017-0607-428528458Search in Google Scholar
Mohammed SF, Mirzovev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2014; 2:113–22.MohammedSFMirzovevSAEdwardsWDDoganAGroganDRDunlaySMRogerVLGertzMADispenzieriAZeldenrustSRRedfieldMMLeft ventricular amyloid deposition in patients with heart failure and preserved ejection fractionJACC Heart Fail201421132210.1016/j.jchf.2013.11.004398453924720917Search in Google Scholar
Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol 2015; 12:91–102.GertzMADispenzieriASherTPathophysiology and treatment of cardiac amyloidosisNat Rev Cardiol2015129110210.1038/nrcardio.2014.16525311231Search in Google Scholar
Gertz MA. Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment. Am J Hematol 2018; 93:1169–80.GertzMAImmunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatmentAm J Hematol20189311698010.1002/ajh.2514930040145Search in Google Scholar
Castaño A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015; 20:163–78.CastañoADrachmanBMJudgeDMaurerMSNatural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugsHeart Fail Rev.2015201637810.1007/s10741-014-9462-7436130225408161Search in Google Scholar
Patel KS, Hawkins PN. Cardiac amyloidosis: where are we today? J Intern Med. 2015; 278:126–44.PatelKSHawkinsPNCardiac amyloidosis: where are we today?J Intern Med.20152781264410.1111/joim.1238326077367Search in Google Scholar
Sandra Ihne, Caroline Morbach, Laura Obici, Giovanni Palladini, Stefan Störk. Amyloidosis in Heart Failure. Curr Heart Fail Rep. 2019; 16:285–303.IhneSandraMorbachCarolineObiciLauraPalladiniGiovanniStörkStefanAmyloidosis in Heart FailureCurr Heart Fail Rep.20191628530310.1007/s11897-019-00446-x31782077Search in Google Scholar
Benson MD, Dasgupta MR. Amyloid cardiomyopathy. J Am Coll Cardiol 2016; 68:25–8.BensonMDDasguptaMRAmyloid cardiomyopathyJ Am Coll Cardiol20166825810.1016/j.jacc.2016.05.00927364046Search in Google Scholar
Gertz MA. Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment. Am J Hematol 2018; 93:1169–80.GertzMAImmunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatmentAm J Hematol20189311698010.1002/ajh.25149Search in Google Scholar
Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy A systematic review. JAMA 2020; 324:79–89.GertzMADispenzieriASystemic amyloidosis recognition, prognosis, and therapy A systematic reviewJAMA2020324798910.1001/jama.2020.549332633805Search in Google Scholar
Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood 2016; 128:159–68.PalladiniGMerliniGWhat is new in diagnosis and management of light chain amyloidosis?Blood20161281596810.1182/blood-2016-01-62979027053535Search in Google Scholar
Kyle RA, Larson DR, Kurtin PJ, Kumar S, Cerhan JR, Therneau TM, Rajkumar SV, Vachon CM, Dispenzieri A. Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc 2019; 94:465–71.KyleRALarsonDRKurtinPJKumarSCerhanJRTherneauTMRajkumarSVVachonCMDispenzieriAIncidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015Mayo Clin Proc2019944657110.1016/j.mayocp.2018.08.041640126230713046Search in Google Scholar
Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, Sipe JD, Westermark P. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2018; 25:215–9.BensonMDBuxbaumJNEisenbergDSMerliniGSaraivaMJMSekijimaYSipeJDWestermarkPAmyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committeeAmyloid201825215910.1080/13506129.2018.154982530614283Search in Google Scholar
Arciello A, Piccoli R, Monti DM. Apolipoprotein A-I: the dual face of a protein. FEBS Lett. 2016; 590:4171–9.ArcielloAPiccoliRMontiDMApolipoprotein A-I: the dual face of a proteinFEBS Lett.20165904171910.1002/1873-3468.1246827790714Search in Google Scholar
Quarta CC, Gonzalez-Lopez E, Gilbertson JA, Botcher N, Rowczenio D, Petrie A, Rezk T, Youngstein T, Mahmood S, Sachchithanantham S, Lachmann HJ, Fontana M, Whelan CJ, Wechalekar AD, Hawkins PN, Gillmore JD. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J. 2017; 38:1905–8.QuartaCCGonzalez-LopezEGilbertsonJABotcherNRowczenioDPetrieARezkTYoungsteinTMahmoodSSachchithananthamSLachmannHJFontanaMWhelanCJWechalekarADHawkinsPNGillmoreJDDiagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosisEur Heart J.2017381905810.1093/eurheartj/ehx047583722928605421Search in Google Scholar
Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood. 2001; 98:714–20.ComenzoRLZhangYMartinezCOsmanKHerreraGAThe tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burdenBlood.2001987142010.1182/blood.V98.3.71411468171Search in Google Scholar
Perfetti V, Casarini S, Palladini G, Vignarelli MC, Klersy C, Diegoli M, Ascari E, Merlini G. Analysis of V (lambda)-J (lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood. 2002; 100:948–53.PerfettiVCasariniSPalladiniGVignarelliMCKlersyCDiegoliMAscariEMerliniGAnalysis of V (lambda)-J (lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segmentBlood.20021009485310.1182/blood-2002-01-011412130507Search in Google Scholar
Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain associated amyloidosis (AL). Blood. 2003; 101:3801–8.AbrahamRSGeyerSMPrice-TroskaTLAllmerCKyleRAGertzMAFonsecaRImmunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain associated amyloidosis (AL)Blood.20031013801810.1182/blood-2002-09-270712515719Search in Google Scholar
Perfetti V, Palladini G, Casarini S, Navazza V, Rognoni P, Obici L, Invernizzi R, Perlini S, Klersy C, Merlini G. The repertoire of lambda light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood. 2012; 119:144–50.PerfettiVPalladiniGCasariniSNavazzaVRognoniPObiciLInvernizziRPerliniSKlersyCMerliniGThe repertoire of lambda light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44Blood.20121191445010.1182/blood-2011-05-35578422067386Search in Google Scholar
Kourelis TV, Dasari S, Theis JD, Ramirez-Alvarado M, Kurtin PJ, Gertz MA, Zeldenrust SR, Zenka RM, Dogan A, Dispenzieri A. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. Blood. 2017; 129:299–306.KourelisTVDasariSTheisJDRamirez-AlvaradoMKurtinPJGertzMAZeldenrustSRZenkaRMDoganADispenzieriAClarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometryBlood.201712929930610.1182/blood-2016-10-74399727856462Search in Google Scholar
Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, Obici L, Bradwell AR, Melzi D’Eril GV, Fogari R, Moratti R, Merlini G. Circulating amyloidogenic free light chains and serum Nterminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006; 107:3854–8.PalladiniGLavatelliFRussoPPerliniSPerfettiVBosoniTObiciLBradwellARMelzi D’ErilGVFogariRMorattiRMerliniGCirculating amyloidogenic free light chains and serum Nterminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in ALBlood.20061073854810.1182/blood-2005-11-438516434487Search in Google Scholar
Milani P, Merlini G, Palladini G. Light chain amyloidosis. Mediterr J Hematol Infect Dis. 2018;10: e2018022.MilaniPMerliniGPalladiniGLight chain amyloidosisMediterr J Hematol Infect Dis201810e201802210.4084/mjhid.2018.022Search in Google Scholar
Lin HM, Gao X, Cooke CE, Berg D, Labotka R, Faller DV, Seal B, Hari P. Disease burden of systemic light-chain amyloidosis: a systematic literature review. Curr Med Res Opin. 2017; 33:1017–31.LinHMGaoXCookeCEBergDLabotkaRFallerDVSealBHariPDisease burden of systemic light-chain amyloidosis: a systematic literature reviewCurr Med Res Opin.20173310173110.1080/03007995.2017.129793028277869Search in Google Scholar
Merlini G, Dispenzieri A, Sanchorawala V, Schonland SO, Palladini G, Hawkins PN, Gertz MA. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4:38.MerliniGDispenzieriASanchorawalaVSchonlandSOPalladiniGHawkinsPNGertzMASystemic immunoglobulin light chain amyloidosisNat Rev Dis Primers201843810.1038/s41572-018-0034-330361521Search in Google Scholar
Fine NM, Davis MK, Anderson K, Delgado DH, Giraldeau G, Kitchlu A, Massie R, Narayan J, Swiggum E, Venner CP, Ducharme A, Galant NJ, Hahn C, Howlett JG, Mielniczuk L, Parent MC, Reece D, Royal V, Toma M, Virani SA, Zieroth S. Canadian Cardiovascular Society/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis. Can J Cardiol. 2020;36:322–34.FineNMDavisMKAndersonKDelgadoDHGiraldeauGKitchluAMassieRNarayanJSwiggumEVennerCPDucharmeAGalantNJHahnCHowlettJGMielniczukLParentMCReeceDRoyalVTomaMViraniSAZierothSCanadian Cardiovascular Society/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosisCan J Cardiol2020363223410.1016/j.cjca.2019.12.03432145862Search in Google Scholar
Khanna S, Wen I, Bhat A, Chen HHL, Gan GCH, Pathan F, Tan TC. The role of multi-modality imaging in the diagnosis of cardiac amyloidosis: a focused update. Front Cardiovasc Med. 2020;7:212.KhannaSWenIBhatAChenHHLGanGCHPathanFTanTCThe role of multi-modality imaging in the diagnosis of cardiac amyloidosis: a focused updateFront Cardiovasc Med2020721210.3389/fcvm.2020.590557766168933195479Search in Google Scholar
González-López E, López-Sainz Á, Garcia-Pavia P. Diagnosis and treatment of transthyretin cardiac amyloidosis. Progress and hope. Rev Esp Cardiol. 2017; 70:991–1004.González-LópezELópez-SainzÁGarcia-PaviaPDiagnosis and treatment of transthyretin cardiac amyloidosis. Progress and hopeRev Esp Cardiol.201770991100410.1016/j.rec.2017.05.03628870641Search in Google Scholar
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019; 73:2872–91.RubergFLGroganMHannaMKellyJWMaurerMSTransthyretin amyloid cardiomyopathy: JACC state-of-the-art reviewJ Am Coll Cardiol.20197328729110.1016/j.jacc.2019.04.003672418331171094Search in Google Scholar
Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart 2011; 97:75–84.DubreySWHawkinsPNFalkRHAmyloid diseases of the heart: assessment, diagnosis, and referralHeart201197758410.1136/hrt.2009.19040521148582Search in Google Scholar
Nakagawa M, Sekijima Y, Yazaki M, Tojo K, Yoshinaga T, Doden T, Koyama J, Yanagisawa S, Ikeda SI. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid. 2016; 23:58–63.NakagawaMSekijimaYYazakiMTojoKYoshinagaTDodenTKoyamaJYanagisawaSIkedaSICarpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosisAmyloid.201623586310.3109/13506129.2015.113579226852880Search in Google Scholar
Westermark P, Westermark GT, Suhr OB, Berg S. Transthyretin derived amyloidosis: probably a common cause of lumbar spinal stenosis. Ups J Med Sci. 2014; 119:223–8.WestermarkPWestermarkGTSuhrOBBergSTransthyretin derived amyloidosis: probably a common cause of lumbar spinal stenosisUps J Med Sci.2014119223810.3109/03009734.2014.895786411676124620715Search in Google Scholar
Adams D, Ando Y, Beirão JM, Coelho T, Gertz MA, Gillmore JD, Hawkins PN, Lousada I, Suhr OB, Merlini G. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2020; 268:2109–22.AdamsDAndoYBeirãoJMCoelhoTGertzMAGillmoreJDHawkinsPNLousadaISuhrOBMerliniGExpert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathyJ Neurol.202026821092210.1007/s00415-019-09688-0817991231907599Search in Google Scholar
Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I) cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet Med. 2017; 19:733–42.BuxbaumJNRubergFLTransthyretin V122I (pV142I) cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African AmericansGenet Med.2017197334210.1038/gim.2016.200550949828102864Search in Google Scholar
Agha AM, Parwani P, Guha A, Durand JB, Iliescu CA, Hassan S, Palaskas NL, Gladish G, Kim PY, Lopez-Mattei J. Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosis. Open Heart. 2018;5:e000881–e000881AghaAMParwaniPGuhaADurandJBIliescuCAHassanSPalaskasNLGladishGKimPYLopez-MatteiJRole of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosisOpen Heart20185e000881e00088110.1136/openhrt-2018-000881617326730305910Search in Google Scholar
Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure. Arch Intern Med 2005; 165:1425–9.NgBConnorsLHDavidoffRSkinnerMFalkRHSenile systemic amyloidosis presenting with heart failureArch Intern Med20051651425910.1001/archinte.165.12.142515983293Search in Google Scholar
Perfetto F, Bergesio F, Emdin M, Capelli F. Troponins in cardiac amyloidosis: multipurpose markers. Nat Rev Cardiol. 2014; 11:179.PerfettoFBergesioFEmdinMCapelliFTroponins in cardiac amyloidosis: multipurpose markersNat Rev Cardiol20141117910.1038/nrcardio.2013.129-c124469674Search in Google Scholar
Neben-Wittich MA, Wittich CM, Mueller PS, Larson DR, Gertz MA, Edwards WD. Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis. Am J Med. 2005;118:1287.Neben-WittichMAWittichCMMuellerPSLarsonDRGertzMAEdwardsWDObstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosisAm J Med2005118128710.1016/j.amjmed.2005.06.01716271914Search in Google Scholar
Dorbala S, Vangala D, Bruyere J, Quarta C, Kruger J, Padera R, Foster C, Hanley M, Di Carli MF, Falk R. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014;2:358–67.DorbalaSVangalaDBruyereJQuartaCKrugerJPaderaRFosterCHanleyMDi CarliMFFalkRCoronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosisJACC Heart Fail201423586710.1016/j.jchf.2014.03.009412714525023822Search in Google Scholar
Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 2017; 135:1357–77.MaurerMSElliottPComenzoRSemigranMRapezziCAddressing common questions encountered in the diagnosis and management of cardiac amyloidosisCirculation201713513577710.1161/CIRCULATIONAHA.116.024438539241628373528Search in Google Scholar
Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, Grogan M, Kristen AV, Lousada I, Nativi-Nicolau J, Quarta CC, Rapezzi C, Ruberg FL, Witteles R, Merlini G. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12: e006075.MaurerMSBokhariSDamyTDorbalaSDrachmanBMFontanaMGroganMKristenAVLousadaINativi-NicolauJQuartaCCRapezziCRubergFLWittelesRMerliniGExpert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosisCirc Heart Fail201912e00607510.1161/CIRCHEARTFAILURE.119.006075673665031480867Search in Google Scholar
Zhongwei Cheng, Kongbo Zhu, Zhuang Tian, Dachun Zhao., Quancai Cui M.D. Quan Fang M.D. The findings of electrocardiography in patients with cardiac amyloidosis. Ann Noninvasive Electrocardiol. 2013; 18:157–62.ChengZhongweiZhuKongboTianZhuangZhaoDachunCuiQuancaiM.D.FangQuanM.D.The findings of electrocardiography in patients with cardiac amyloidosis. Ann Noninvasive Electrocardiol.2013181576210.1111/anec.12018693243223530486Search in Google Scholar
Dungu JN, Sattianayagam PT, Whelan CJ, Gibbs SD, Pinney JH, Banypersad SM, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Hawkins PN, Anderson LJ. The electrocardio graphic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in afro-caribbean patients. Am Heart J 2012; 164:72–9.DunguJNSattianayagamPTWhelanCJGibbsSDPinneyJHBanypersadSMRowczenioDGilbertsonJALachmannHJWechalekarAGillmoreJDHawkinsPNAndersonLJThe electrocardio graphic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in afro-caribbean patientsAm Heart J201216472910.1016/j.ahj.2012.04.01322795285Search in Google Scholar
Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005; 95:535–7.MurtaghBHammillSCGertzMAKyleRATajikAJGroganMElectrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvementAm J Cardiol200595535710.1016/j.amjcard.2004.10.02815695149Search in Google Scholar
Rahman JE, Helou EF, Gelzer-Bell R, Thompson RE, Kuo C, Rodriguez ER, Hare JM, Baughman KL, Kasper EK. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 2004; 43:410–5.RahmanJEHelouEFGelzer-BellRThompsonREKuoCRodriguezERHareJMBaughmanKLKasperEKNoninvasive diagnosis of biopsy-proven cardiac amyloidosisJ Am Coll Cardiol200443410510.1016/j.jacc.2003.08.04315013123Search in Google Scholar
Austin BA, Duffy B, Tan C, Rodriguez ER, Starling RC, Desai MY. Comparison of functional status, electrocardiographic, and echo car diographic parameters to mortality in endomyocardial-biopsy proven cardiac amyloidosis. Am J Cardiol 2009; 103:1429–33.AustinBADuffyBTanCRodriguezERStarlingRCDesaiMYComparison of functional status, electrocardiographic, and echo car diographic parameters to mortality in endomyocardial-biopsy proven cardiac amyloidosisAm J Cardiol200910314293310.1016/j.amjcard.2009.01.36119427441Search in Google Scholar
Mussinelli R, Salinaro F, Alogna A, Boldrini M, Raimondi A, Musca F, Palladini G, Merlini G, Perlini S. Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. Ann Noninvasive Electrocardiol. 2013; 18:271–80.MussinelliRSalinaroFAlognaABoldriniMRaimondiAMuscaFPalladiniGMerliniGPerliniSDiagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosisAnn Noninvasive Electrocardiol.2013182718010.1111/anec.12036693219223714086Search in Google Scholar
Namdar M, Steffel J, Jetzer S, Schmied C, Hurlimann D, Camici GG, Bayrak F, Ricciardi D, Rao JY, de Asmundis C, Chiercia GB, Sarkozy A, Luscher TF, Jenni R, Duru F, Brugada P. Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease. Am J Cardiol 2012; 109:587–93.NamdarMSteffelJJetzerSSchmiedCHurlimannDCamiciGGBayrakFRicciardiDRaoJYde AsmundisCChierciaGBSarkozyALuscherTFJenniRDuruFBrugadaPValue of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry diseaseAm J Cardiol20121095879310.1016/j.amjcard.2011.09.05222105784Search in Google Scholar
Perlini S, Salinaro F, Cappelli F, Perfetto F, Bergesio F, Alogna A, Mussinelli R, Boldrini M, Raimondi A, Musca F, Palladini G, Merlini G. Prognostic value of fragmented QRS in cardiac AL amyloidosis. Int J Cardiol 2013; 167:2156–61.PerliniSSalinaroFCappelliFPerfettoFBergesioFAlognaAMussinelliRBoldriniMRaimondiAMuscaFPalladiniGMerliniGPrognostic value of fragmented QRS in cardiac AL amyloidosisInt J Cardiol201316721566110.1016/j.ijcard.2012.05.09722748496Search in Google Scholar
Granstam SO, Rosengren S, Vedin O, Kero T, Sorensen J, Carlson K, Flachsckampf FA, Wikstrom G. Evaluation of patients with cardiac amyloidosis using echocardiography, ECG and right heart catheterization. Amyloid 2013; 20:27–33.GranstamSORosengrenSVedinOKeroTSorensenJCarlsonKFlachsckampfFAWikstromGEvaluation of patients with cardiac amyloidosis using echocardiography, ECG and right heart catheterizationAmyloid201320273310.3109/13506129.2012.76196723339421Search in Google Scholar
Boldrini M, Salinaro F, Mussinelli R, Raimondi A, Alogna A, Musca F, Palladini G, Merlini G, Perlini S. Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac al amyloidosis. Ann Noninvasive Electrocardiol 2013; 18:327–35.BoldriniMSalinaroFMussinelliRRaimondiAAlognaAMuscaFPalladiniGMerliniGPerliniSPrevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac al amyloidosisAnn Noninvasive Electrocardiol2013183273510.1111/anec.12032693203523879272Search in Google Scholar
Reyners AK, Hazenberg BP, Reitsma WD, Smit AJ. Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. Eur Heart J 2002; 23:157–61.ReynersAKHazenbergBPReitsmaWDSmitAJHeart rate variability as a predictor of mortality in patients with AA and AL amyloidosisEur Heart J2002231576110.1053/euhj.2001.297211785998Search in Google Scholar
Falk RH, Quarta CC, Dorbala S. How to image cardiac amyloidosis. Circ Cardiovasc Imaging. 2014; 7:552–62.FalkRHQuartaCCDorbalaSHow to image cardiac amyloidosisCirc Cardiovasc Imaging.201475526210.1161/CIRCIMAGING.113.001396411830824847009Search in Google Scholar
Bradshaw SH, Veinot JP. Cardiac amyloidosis. Curr Opin Cardiol 2012; 27:143–7.BradshawSHVeinotJPCardiac amyloidosisCurr Opin Cardiol201227143710.1097/HCO.0b013e32834fdc7e22314298Search in Google Scholar
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lackmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AWJM, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazemberg BP, Rapezzi C, Hawkins PN. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133:2404–12.GillmoreJDMaurerMSFalkRHMerliniGDamyTDispenzieriAWechalekarADBerkJLQuartaCCGroganMLackmannHJBokhariSCastanoADorbalaSJohnsonGBGlaudemansAWJMRezkTFontanaMPalladiniGMilaniPGuidalottiPLFlatmanKLaneTVonbergFWWhelanCJMoonJCRubergFLMillerEJHuttDFHazembergBPRapezziCHawkinsPNNonbiopsy diagnosis of cardiac transthyretin amyloidosisCirculation201613324041210.1161/CIRCULATIONAHA.116.02161227143678Search in Google Scholar
Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016; 68:1014–20.GroganMScottCGKyleRAZeldenrustSRGertzMALinGKlarichKWMillerWLMaleszewskiJJDispenzieriANatural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging systemJ Am Coll Cardiol.20166810142010.1016/j.jacc.2016.06.03327585505Search in Google Scholar
Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018; 39:2799–806.GillmoreJDDamyTFontanaMHutchinsonMLachmannHJMartinez-NaharroAQuartaCCRezkTWhelanCJGonzalez-LopezELaneTGilbertsonJARowczenioDPetrieAHawkinsPNA new staging system for cardiac transthyretin amyloidosisEur Heart J.201839279980610.1093/eurheartj/ehx58929048471Search in Google Scholar
Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna M, Plana JC, Marwick TH, Thomas JD. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98:1442–8.PhelanDCollierPThavendiranathanPPopovicZBHannaMPlanaJCMarwickTHThomasJDRelative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosisHeart2012981442810.1136/heartjnl-2012-30235322865865Search in Google Scholar
Pagourelias ED, Duchenne J, Mirea O, Vovas G, Van Cleemput J, Delforge M, Kuznetsova T, Boagert J, Voigt JU. The relation of ejection fraction and global longitudinal strain in amyloidosis: implications for differential diagnosis. JACC Cardiovasc Imaging. 2016; 9:1358–9.PagoureliasEDDuchenneJMireaOVovasGVan CleemputJDelforgeMKuznetsovaTBoagertJVoigtJUThe relation of ejection fraction and global longitudinal strain in amyloidosis: implications for differential diagnosisJACC Cardiovasc Imaging.201691358910.1016/j.jcmg.2015.11.01326897665Search in Google Scholar
Pagourelias ED, Mirea O, Duchenne J, Van Cleemput J, Delforge M, Bogaert J, Kuznetsova T, Voigt JU. Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging. 2017;10: e005588.PagoureliasEDMireaODuchenneJVan CleemputJDelforgeMBogaertJKuznetsovaTVoigtJUEcho parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parametersCirc Cardiovasc Imaging201710e00558810.1161/CIRCIMAGING.116.00558828298286Search in Google Scholar
Ono K, Ishimaru G, Hayashi M, Bae Y, Ito T, Izumo T, Murata K. The imaging diagnosis of less advanced cases of cardiac amyloidosis: the relative apical sparing pattern. Intern Med. 2017; 56:315–9.OnoKIshimaruGHayashiMBaeYItoTIzumoTMurataKThe imaging diagnosis of less advanced cases of cardiac amyloidosis: the relative apical sparing patternIntern Med.201756315910.2169/internalmedicine.56.7610534845628154276Search in Google Scholar
Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P, Radu C, Guendouz S, Couetil JP, Benhaiem N, Hittinger L, Dubois-Rande JL, Plante-Bordeneuve V, Mohty D, Feux JF, Damy T. Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis. JACC Cardiovasc Imaging. 2016;9:126–38.TernacleJBodezDGuellichAAudureauERappeneauSLimPRaduCGuendouzSCouetilJPBenhaiemNHittingerLDubois-RandeJLPlante-BordeneuveVMohtyDFeuxJFDamyTCauses and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosisJACC Cardiovasc Imaging201691263810.1016/j.jcmg.2015.05.01426777222Search in Google Scholar
Knight DS, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Kotecha T, Francis R, Rezk T, Quarta CC, Whelan CJ, Lachmann HL, Wechalekar AD, Gillmore JD, Moon JC, Hawkins PN, Fontana M. Cardiac sructural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. JACC: Cardiovascular Imaging. 2019;12:823–33.KnightDSZumboGBarcellaWSteedenJAMuthuranguVMartinez-NaharroATreibelTAAbdel-GadirABulluckHKotechaTFrancisRRezkTQuartaCCWhelanCJLachmannHLWechalekarADGillmoreJDMoonJCHawkinsPNFontanaMCardiac sructural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic rolesJACC: Cardiovascular Imaging20191282333Search in Google Scholar
Pun SC, Landau HJ, Riedel ER, Jordan J, Yu AF, Hassoun H, Chen CL, Steingart RM, Liu JE. Prognostic and added value of two-dimensional global longitudinal strain for prediction of survival in patients with light chain amyloidosis undergoing autologous hematopoietic cell transplantation. J Am Soc Echocardiogr. 2018;31:64–70.PunSCLandauHJRiedelERJordanJYuAFHassounHChenCLSteingartRMLiuJEPrognostic and added value of two-dimensional global longitudinal strain for prediction of survival in patients with light chain amyloidosis undergoing autologous hematopoietic cell transplantationJ Am Soc Echocardiogr201831647010.1016/j.echo.2017.08.017Search in Google Scholar
Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, Nair AP, Nativi-Nicolau J, Ruberg FL, American Heart Association heart failure and transplantation committee of the council on clinical cardiology. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142:7–22.KittlesonMMMaurerMSAmbardekarAVBullock-PalmerRPChangPPEisenHJNairAPNativi-NicolauJRubergFLAmerican Heart Association heart failure and transplantation committee of the council on clinical cardiology. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart AssociationCirculation202014272210.1161/CIR.0000000000000792Search in Google Scholar
Jurcut R, Onciul S, Adam R, Stan C, Coriu D, Rapezzi C, Popescu BA. Multimodality imaging in cardiac amyloidosis: a primer for cardiologists. Eur Heart J Cardiovasc Imaging, 2020;21:833–44.JurcutROnciulSAdamRStanCCoriuDRapezziCPopescuBAMultimodality imaging in cardiac amyloidosis: a primer for cardiologistsEur Heart J Cardiovasc Imaging2020218334410.1093/ehjci/jeaa063Search in Google Scholar
Roger-Rollé A, Cariou E, Rguez K, Fournier P, Lavie-Badie Y, Blanchard V, Roncalli J, Galinier M, Carrie D, Lairez O, Toulouse Amyloidosis Research Network collaborators. Can myocardial work indices contribute to the exploration of patients with cardiac amyloidosis? Open Heart 2020;7:e001346.Roger-RolléACariouERguezKFournierPLavie-BadieYBlanchardVRoncalliJGalinierMCarrieDLairezOToulouse Amyloidosis Research Network collaboratorsCan myocardial work indices contribute to the exploration of patients with cardiac amyloidosis?Open Heart20207e00134610.1136/openhrt-2020-001346Search in Google Scholar
Sakamoto M, Funada A, Amaki M, Ohara T, Hasegawa T, Sugano Y, Kanzaky H, Kitakaze M, Anzai T. More impaired diastolic function of light chain amyloidosis contributes to poor prognosis compared with transthyretin amyloidosis: result from longitudinal study of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol. 2015;65: A935.SakamotoMFunadaAAmakiMOharaTHasegawaTSuganoYKanzakyHKitakazeMAnzaiTMore impaired diastolic function of light chain amyloidosis contributes to poor prognosis compared with transthyretin amyloidosis: result from longitudinal study of biopsy-proven cardiac amyloidosisJ Am Coll Cardiol201565A93510.1016/S0735-1097(15)60935-4Search in Google Scholar
Stricagnoli M, Cameli M, Incampo E, Lunghetti S, Mondillo S. Speckle tracking echocardiography in cardiac amyloidosis. Heart Fail Rev. 2019; 24:701–7.StricagnoliMCameliMIncampoELunghettiSMondilloSSpeckle tracking echocardiography in cardiac amyloidosisHeart Fail Rev.201924701710.1007/s10741-019-09796-z30989593Search in Google Scholar
Clemmensen TS, Eiskjær H, Mikkelsen F, Granstam SO, Flachskampf FA, Sørensen J, Poulsen SH. Left ventricular pressure-strain-derived myocardial work at rest and during exercise in patients with cardiac amyloidosis. J Am Soc Echocardiogr. 2020; 33:573–82.ClemmensenTSEiskjærHMikkelsenFGranstamSOFlachskampfFASørensenJPoulsenSHLeft ventricular pressure-strain-derived myocardial work at rest and during exercise in patients with cardiac amyloidosisJ Am Soc Echocardiogr.2020335738210.1016/j.echo.2019.11.01832061410Search in Google Scholar
Dungu JN, Valencia O, Pinney JH, Gibbs SDJ, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Whelan CJ, Hawkins PN, Anderson LJ. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7:133–42.DunguJNValenciaOPinneyJHGibbsSDJRowczenioDGilbertsonJALachmannHJWechalekarAGillmoreJDWhelanCJHawkinsPNAndersonLJCMR-based differentiation of AL and ATTR cardiac amyloidosisJACC Cardiovasc Imaging201471334210.1016/j.jcmg.2013.08.01524412186Search in Google Scholar
Oda S, Utsunomiya D, Nakaura T, Takashio S, Izumiya Y, Tsujita K, Ueda M, Yamashita T, Ando Y, Kawano Y, Okuno Y, Hata H, Yamashita Y. Role of noninvasive diagnostic imaging in cardiac amyloidosis: a review. Cardiovasc Imaging Asia. 2018; 2:97–106.OdaSUtsunomiyaDNakauraTTakashioSIzumiyaYTsujitaKUedaMYamashitaTAndoYKawanoYOkunoYHataHYamashitaYRole of noninvasive diagnostic imaging in cardiac amyloidosis: a reviewCardiovasc Imaging Asia.201829710610.22468/cvia.2018.00059Search in Google Scholar
Fontana M, Chung R, Hawkins PN, Moon JC. Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev 2015; 20:133–44.FontanaMChungRHawkinsPNMoonJCCardiovascular magnetic resonance for amyloidosisHeart Fail Rev2015201334410.1007/s10741-014-9470-725549885Search in Google Scholar
Wan K, Sun J, Han Y, Liu H, Yang D, Li W, Wang J, Cheng W, Zhang Q, Zeng Z, Chen Y. Increased prognostic value of query amyloid late enhancement score in light-chain cardiac amyloidosis. Circ J. 2018;82:739–46.WanKSunJHanYLiuHYangDLiWWangJChengWZhangQZengZChenYIncreased prognostic value of query amyloid late enhancement score in light-chain cardiac amyloidosisCirc J2018827394610.1253/circj.CJ-17-046429093431Search in Google Scholar
Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013; 6:488–97.KaramitsosTDPiechnikSKBanypersadSMFontanaMNtusiNBFerreiraVMWhelanCJMyersonSGRobsonMDHawkinsPNNeubauerSMoonJCNoncontrast T1 mapping for the diagnosis of cardiac amyloidosisJACC Cardiovasc Imaging.201364889710.1016/j.jcmg.2012.11.01323498672Search in Google Scholar
Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, Piechnik SK, Whelan CJ, Herrey AS, Gillmore JD, Lachmann HJ, Wechalekar AD, Hawkins PN, Moon JC. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015; 21:244–51.BanypersadSMFontanaMMaestriniVSadoDMCapturGPetrieAPiechnikSKWhelanCJHerreyASGillmoreJDLachmannHJWechalekarADHawkinsPNMoonJCT1 mapping and survival in systemic light-chain amyloidosisEur Heart J.2015212445110.1093/eurheartj/ehu444430159825411195Search in Google Scholar
Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005; 46:1076–84.PeruginiEGuidalottiPLSalviFCookeRMTPettinatoCRivaLLeoneOFarsadMCilibertiPBacchi-ReggianiLFallaniFBranziARapezziCNoninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphyJ Am Coll Cardiol.20054610768410.1016/j.jacc.2005.05.07316168294Search in Google Scholar
Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SDJ, Venner CP, Wassef N, McCarthy CA, Gillbertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2: e000098.PinneyJHWhelanCJPetrieADunguJBanypersadSMSattianayagamPWechalekarAGibbsSDJVennerCPWassefNMcCarthyCAGillbertsonJARowczenioDHawkinsPNGillmoreJDLachmannHJSenile systemic amyloidosis: clinical features at presentation and outcomeJ Am Heart Assoc20132e00009810.1161/JAHA.113.000098364725923608605Search in Google Scholar
Kim D, Choi J-O, Kim K, Kim SJ, Jeon E-S. Untangling amyloidosis: recent advances in cardiac amyloidosis. Int J Heart Fail. 2020; 2:231–9.KimDChoiJ-OKimKKimSJJeonE-SUntangling amyloidosis: recent advances in cardiac amyloidosisInt J Heart Fail.20202231910.36628/ijhf.2020.0016Search in Google Scholar
van Gameren II, Hazenberg BP, Bijzet J, van Rijswijk MH. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum. 2006; 54:2015–21.van GamerenIIHazenbergBPBijzetJvan RijswijkMHDiagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practiceArthritis Rheum.20065420152110.1002/art.2190216732553Search in Google Scholar
Swan N, Skinner M, O’Hara CJ. Bone marrow core biopsy specimens in AL (primary) amyloidosis. A morphologic and immunohistochemical study of 100 cases. Am J Clin Pathol. 2003; 120:610–6.SwanNSkinnerMO’HaraCJBone marrow core biopsy specimens in AL (primary) amyloidosis. A morphologic and immunohistochemical study of 100 casesAm J Clin Pathol.2003120610610.1309/PFUGHBX0TY20E08USearch in Google Scholar
Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002; 346:1786–91.LachmannHJBoothDRBoothSEBybeeAGilbertsonJAGillmoreJDPepysMBHawkinsPNMisdiagnosis of hereditary amyloidosis as AL (primary) amyloidosisN Engl J Med.200234617869110.1056/NEJMoa01335412050338Search in Google Scholar
Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009; 114:4957–9.VranaJAGamezJDMaddenBJTheisJDBergenHR3rdDoganAClassification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimensBlood.20091144957910.1182/blood-2009-07-23072219797517Search in Google Scholar
Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulus MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013; 121:3420–7.WechalekarADSchonlandSOKastritisEGillmoreJDDimopoulusMALaneTFoliAFoardDMilaniPRanniganLHegenbartUHawkinsPNMerliniGPalladiniGA European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosisBlood20131213420710.1182/blood-2012-12-47306623479568Search in Google Scholar
Dispenzieri A, Gertz MA, Kyle Lacy MQ, Burrit MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, McGregor CGA, Jaffe AS. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004; 104:1881–7.DispenzieriAGertzMAKyle LacyMQBurritMFTherneauTMMcConnellJPLitzowMRGastineauDATefferiAInwardsDJMicallefINAnsellSMPorrataLFElliottMAHoganWJRajkumarSVFonsecaRGreippPRWitzigTELustJAZeldenrustSRSnowDSHaymanSRMcGregorCGAJaffeASPrognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationBlood.20041041881710.1182/blood-2004-01-039015044258Search in Google Scholar
Palladini G, Foli A, Milani P, Russo P, Albertini R, Lavatelli, Obici L, Perlini S, Moratti R, Merlini G. Best use of cardiac biomarkers in patients with AL Amyloidosis and renal failure. Am J Hematol 2012; 87:465–71.PalladiniGFoliAMilaniPRussoPAlbertiniRLavatelliObiciLPerliniSMorattiRMerliniGBest use of cardiac biomarkers in patients with AL Amyloidosis and renal failureAm J Hematol2012874657110.1002/ajh.2314122389105Search in Google Scholar
Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain (AL) amyloidosis. Leukemia 2012; 26:2317–25.ComenzoRLReeceDPalladiniGSeldinDSanchorawalaVLandauHFalkRWellsKSolomonAWechalekarAZonderJDispenzieriAGertzMStreicherHSkinnerMKyleRAMerliniGConsensus guidelines for the conduct and reporting of clinical trials in systemic light-chain (AL) amyloidosisLeukemia20122623172510.1038/leu.2012.10022475872Search in Google Scholar
Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schonland S, Hegebart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. New criteria for response to treatment in Immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes. J Clin Oncol 2012; 30:4541–9.PalladiniGDispenzieriAGertzMAKumarSWechalekarAHawkinsPNSchonlandSHegebartUComenzoRKastritisEDimopoulosMAJaccardAKlersyCMerliniGNew criteria for response to treatment in Immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomesJ Clin Oncol2012304541910.1200/JCO.2011.37.761423091105Search in Google Scholar
Jercan A., Ene A., Jurcut R, Draghici M, Badelita S, Dragomir M, Dobrea C, Popescu M, Jardan D, Stoica E, Iacob S, Codita I, Stan C, Coriu D. Clinical characteristics in patients with hereditary amyloidosis with Glu54Gln transthyretin identified in the Romanian population. Orphanet J Rare Dis. 2020; 15:34.JercanA.EneA.JurcutRDraghiciMBadelitaSDragomirMDobreaCPopescuMJardanDStoicaEIacobSCoditaIStanCCoriuDClinical characteristics in patients with hereditary amyloidosis with Glu54Gln transthyretin identified in the Romanian populationOrphanet J Rare Dis2020153410.1186/s13023-020-1309-9699331332000831Search in Google Scholar
Caobelli F, Braun M, Haaf P, Wild D, Zellweger MJ. Quantitative (99m)Tc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores. J Nucl Cardiol. 2020; 27:1456–63.CaobelliFBraunMHaafPWildDZellwegerMJQuantitative (99m)Tc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scoresJ Nucl Cardiol.20202714566310.1007/s12350-019-01893-831538322Search in Google Scholar
McVeigh T, Tennyson C. Understanding and recognizing cardiac amyloidosis. JAAPA. 2020; 33:16–20.McVeighTTennysonCUnderstanding and recognizing cardiac amyloidosisJAAPA.202033162010.1097/01.JAA.0000697236.11386.3a32941304Search in Google Scholar
Bonderman D, Polzl G, Ablasser K, Agis H, Aschauer S, Grumbach M, Binder C, Dorler J, Duca F, Ebner C, Hacker M, Kain R, Kammerlander A, Koschutnik M, Kroiss A, Mayr A, Nitsche C, Rainer P, Malmqvist S, Schneider M, Schwarz R, Verheyen N, Weber T, Zaruba M, Eslam R, Hulsmann M, Mascherbauer J. Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wien Klin Wochenschr. 2020; 132:742–61.BondermanDPolzlGAblasserKAgisHAschauerSGrumbachMBinderCDorlerJDucaFEbnerCHackerMKainRKammerlanderAKoschutnikMKroissAMayrANitscheCRainerPMalmqvistSSchneiderMSchwarzRVerheyenNWeberTZarubaMEslamRHulsmannMMascherbauerJDiagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statementWien Klin Wochenschr.20201327426110.1007/s00508-020-01781-z773280733270160Search in Google Scholar
Feng D, Edwards W, Oh J, Chandrasekaran K, Grogan M, Martinez M, Syed I, Hughes D, Lust J, Jaffe A, Gertz M, Klarich K. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007; 116:2420–6.FengDEdwardsWOhJChandrasekaranKGroganMMartinezMSyedIHughesDLustJJaffeAGertzMKlarichKIntracardiac thrombosis and embolism in patients with cardiac amyloidosisCirculation.20071162420610.1161/CIRCULATIONAHA.107.69776317984380Search in Google Scholar
Kapoor P, Thenappan T, Singh E, Kumar S, Greipp P. Cardiac amyloidosis: a practical approach to diagnosis and management. Am J Med. 2011; 124:1006–15.KapoorPThenappanTSinghEKumarSGreippPCardiac amyloidosis: a practical approach to diagnosis and managementAm J Med.201112410061510.1016/j.amjmed.2011.04.01322017778Search in Google Scholar
Teng C, Li P, Bae J, Pan S, Dixon R, Liu Q. Diagnosis and treatment of thransthyretin-related amyloidosis cardiomyopathy. Clin Cardiol. 2020; 43:1223–31.TengCLiPBaeJPanSDixonRLiuQDiagnosis and treatment of thransthyretin-related amyloidosis cardiomyopathyClin Cardiol.20204312233110.1002/clc.23434766165832725834Search in Google Scholar
Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, Berk JL, Bordeneuve V, Schimdt H, Merlini G. Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. J Am Coll Cardiol. 2015; 66:2451–66.GertzMABensonMDDyckPJGroganMCoelhoTCruzMBerkJLBordeneuveVSchimdtHMerliniGDiagnosis, Prognosis, and Therapy of Transthyretin AmyloidosisJ Am Coll Cardiol.20156624516610.1016/j.jacc.2015.09.07526610878Search in Google Scholar
Algalarrondo V, Dinanian S, Juin C, Chemla D, Bennani S, Sebag C, Plante V, Guludec V, Samuel D, Adams D, Slama M. Prophylactic pacemaker implantation in familial amyloid polyneuropathy. Heart Rhythm 2012; 9:1069–75.AlgalarrondoVDinanianSJuinCChemlaDBennaniSSebagCPlanteVGuludecVSamuelDAdamsDSlamaMProphylactic pacemaker implantation in familial amyloid polyneuropathyHeart Rhythm2012910697510.1016/j.hrthm.2012.02.03322387306Search in Google Scholar
Donellan E, Wazni O, Hanna M, Kanj M, Saliba W, Jaber W. Cardiac Resynchronization Therapy for Transthyretin Cardiac Amyloidosis. J Am Heart Assoc. 2020;9 e017335.DonellanEWazniOHannaMKanjMSalibaWJaberWCardiac Resynchronization Therapy for Transthyretin Cardiac AmyloidosisJ Am Heart Assoc20209e01733510.1161/JAHA.120.017335766072432633203Search in Google Scholar
Donellan E, Wazni O, Hanna M, Saliba W, Jaber W, Kanj M. Primary prevention implantable cardioverter-defibrillators in transthyretin cardiac amyloidosis. Pacing Clin Electrophysiol. 2020; 43:1401–3.DonellanEWazniOHannaMSalibaWJaberWKanjMPrimary prevention implantable cardioverter-defibrillators in transthyretin cardiac amyloidosisPacing Clin Electrophysiol.2020431401310.1111/pace.1402332725816Search in Google Scholar
Priori S, Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliot P, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck K, Madrid A, Nikolaou N, Norekval T, Spaulding C, Veldhuisen D. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac Death. The Task Force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology. Eur Heart J. 2015; 36:2793–867.PrioriSLundqvistCMazzantiABlomNBorggrefeMCammJElliotPFitzsimonsDHatalaRHindricksGKirchhofPKjeldsenKKuckKMadridANikolaouNNorekvalTSpauldingCVeldhuisenD2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac Death. The Task Force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of CardiologyEur Heart J.201536279386710.1093/eurheartj/ehv31626320108Search in Google Scholar
Tan N, Mohsin Y, Hodge D, Lacy M, Packer D, Dispenzieri A, Grogan M, Asirvatham S, Madhavan M, McLEOD C. Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol. 2016; 27:1167–73.TanNMohsinYHodgeDLacyMPackerDDispenzieriAGroganMAsirvathamSMadhavanMMcLEODCCatheter ablation for atrial arrhythmias in patients with cardiac amyloidosisJ Cardiovasc Electrophysiol.20162711677310.1111/jce.1304627422772Search in Google Scholar
Spoladore R, Falasconi G, Marcatti M, Maio S, Fiore G, Slavich M, Margonato A, Turco A, Fragasso G. Advances in pharmacotherapy for cardiac amyloidosis. Expert Opin Pharmacother. 2020;31:1–13.SpoladoreRFalasconiGMarcattiMMaioSFioreGSlavichMMargonatoATurcoAFragassoGAdvances in pharmacotherapy for cardiac amyloidosisExpert Opin Pharmacother20203111310.1080/14656566.2020.183615933043721Search in Google Scholar
Kastritis E, Arnulf B, Leieu X, Zamagni E. A randomized phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis. Blood. 2016;128: 646.KastritisEArnulfBLeieuXZamagniEA randomized phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosisBlood201612864610.1182/blood.V128.22.646.646Search in Google Scholar
Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL, Medvedova E, Kovacsovics T, Rosenzweig M, Sanchorawala V, Qin X, Vasey SY, Weiss BM, Vermeulen J, Merlini G, Comenzo RL. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136:71–80.PalladiniGKastritisEMaurerMSZonderJMinnemaMCWechalekarADJaccardALeeHCBummaNKaufmanJLMedvedovaEKovacsovicsTRosenzweigMSanchorawalaVQinXVaseySYWeissBMVermeulenJMerliniGComenzoRLDaratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDABlood2020136718010.1182/blood.2019004460733289732244252Search in Google Scholar
Solomon SD, Adams D, Kristen A, Grogan M, Gonzalez-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan 3rd TH, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O. Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139:431–43.SolomonSDAdamsDKristenAGroganMGonzalez-DuarteAMaurerMSMerliniGDamyTSlamaMSBrannaganTH3rdDispenzieriABerkJLShahAMGargPVaishnawAKarstenVChenJGollobJVestJSuhrOEffects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosisCirculation20191394314310.1161/CIRCULATIONAHA.118.03583130586695Search in Google Scholar
Gertz M, Comenzo R, Landau H, Sanchorawala V, Weiss B, Zonder J, Walling J, Kinney G, Koller M, Schenk D, Guthrie S, Liu E, Liedtke M. NEOD001 demonstrates organ biomarker response in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion cohort of a phase ½ study. Blood. 2016; 128:644.GertzMComenzoRLandauHSanchorawalaVWeissBZonderJWallingJKinneyGKollerMSchenkDGuthrieSLiuELiedtkeMNEOD001 demonstrates organ biomarker response in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion cohort of a phase ½ studyBlood201612864410.1182/blood.V128.22.644.644Search in Google Scholar
Castano A, Helmke S, Alvarez J, Delisle S, Maurer M. Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail. 2012; 18:315–9.CastanoAHelmkeSAlvarezJDelisleSMaurerMDiflunisal for ATTR cardiac amyloidosisCongest Heart Fail.201218315910.1111/j.1751-7133.2012.00303.x372715322747647Search in Google Scholar
Lohrmann G, Pipilas A, Mussinelli R, Gopal DM, Berk JL, Connors LH, Vellanki N, Hellawell J, Siddiqi OK, Fox J, Maurer MS, Ruberg FL. Stabilization of cardiac function with Diflunisal in transthyretin (ATTR) cardiac amyloidosis. J Card Fail. 2020;26:753–9LohrmannGPipilasAMussinelliRGopalDMBerkJLConnorsLHVellankiNHellawellJSiddiqiOKFoxJMaurerMSRubergFLStabilization of cardiac function with Diflunisal in transthyretin (ATTR) cardiac amyloidosisJ Card Fail202026753910.1016/j.cardfail.2019.11.024775887231805416Search in Google Scholar
Maurer M, Schwartz J, Gundapaneni B, Elliot P, Merlini G, Cruz M, Kristen A, Grogan M, Witteles R, Damy T, Drachman B, Shah S, Hanna M, Judge D, Barsdorf A, Huber P, Patterson T, Riley S, Schumacher J, Stewart M, Sultan M, Rapezzi C. ATTR-ACT study investigators: Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007–16.MaurerMSchwartzJGundapaneniBElliotPMerliniGCruzMKristenAGroganMWittelesRDamyTDrachmanBShahSHannaMJudgeDBarsdorfAHuberPPattersonTRileySSchumacherJStewartMSultanMRapezziCATTR-ACT study investigators: Tafamidis treatment for patients with transthyretin amyloid cardiomyopathyN Engl J Med201837910071610.1056/NEJMoa180568930145929Search in Google Scholar
Endo J, Sano M, Izumyia Y, Tsujita K, Nakamura K, Tahara N, Kuwahara K, Inomata T, Ueda M, Sekijima Y, Ando Y, Tsutsui H, Isobe M, Fukuda K. A statement on the appropriate administration of Tafamidis in patients with transthyretin cardiac amyloidosis. Circ J 2019;84: 15–7.EndoJSanoMIzumyiaYTsujitaKNakamuraKTaharaNKuwaharaKInomataTUedaMSekijimaYAndoYTsutsuiHIsobeMFukudaKA statement on the appropriate administration of Tafamidis in patients with transthyretin cardiac amyloidosisCirc J20198415710.1253/circj.CJ-19-081131735731Search in Google Scholar
Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang, CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plante-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan 3rd TH, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11–21.AdamsDGonzalez-DuarteAO’RiordanWDYangCCUedaMKristenAVTournevISchmidtHHCoelhoTBerkJLLinKPVitaGAttarianSPlante-BordeneuveVMezeiMMCampistolJMBuadesJBrannaganTH3rdKimBJOhJParmanYSekijimaYHawkinsPNSolomonSDPolydefkisMDyckPJGandhiPJGoyalSChenJStrahsALNochurSVSweetserMTGargPPVaishnawAKGollobJASuhrOBPatisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosisN Engl J Med2018379112110.1056/NEJMoa171615329972753Search in Google Scholar
Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plante-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheiberg M, Brannagan 3rd TH, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceicao I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–31.BensonMDWaddington-CruzMBerkJLPolydefkisMDyckPJWangAKPlante-BordeneuveVBarrosoFAMerliniGObiciLScheibergMBrannaganTH3rdLitchyWJWhelanCDrachmanBMAdamsDHeitnerSBConceicaoISchmidtHHVitaGCampistolJMGamezJGorevicPDGaneEShahAMSolomonSDMoniaBPHughesSGKwohTJMcEvoyBWJungSWBakerBFAckermannEJGertzMACoelhoTInotersen treatment for patients with hereditary transthyretin amyloidosisN Engl J Med2018379223110.1056/NEJMoa171679329972757Search in Google Scholar
Scully PR, Patel KP, Treibel TA, Thornton GD, Hughes RK, Chadalavada S, Katsoulis M, Hartman N, Fontana M, Pugliese F, Sabharwal N, Newton JD, Kelion A, Ozkor M, Kennon S, Mullen M, Lloyd G, Menezes LJ, Hawkins PN, Moon JC. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020;41:2759–67.ScullyPRPatelKPTreibelTAThorntonGDHughesRKChadalavadaSKatsoulisMHartmanNFontanaMPuglieseFSabharwalNNewtonJDKelionAOzkorMKennonSMullenMLloydGMenezesLJHawkinsPNMoonJCPrevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantationEur Heart J20204127596710.1093/eurheartj/ehaa170739532932267922Search in Google Scholar
Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, Wollenweber T, Ahmed N, Thornton GD, Kelion AD, Sabharwal N, Newton JD, Ozkor M, Kennon S, Mullen M, Lloyd G, Fontana M, Hawkins PN, Pugliese F, Menezes LJ, Moon JC, Mascherbauer J, Treibel TA. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol. 2021;77:128–39.NitscheCScullyPRPatelKPKammerlanderAAKoschutnikMDonaCWollenweberTAhmedNThorntonGDKelionADSabharwalNNewtonJDOzkorMKennonSMullenMLloydGFontanaMHawkinsPNPuglieseFMenezesLJMoonJCMascherbauerJTreibelTAPrevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosisJ Am Coll Cardiol2021771283910.1016/j.jacc.2020.11.006780526733181246Search in Google Scholar
Koike H, Katsuno M. Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies. Neurol Ther 2020; 9:317–33.KoikeHKatsunoMTransthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapiesNeurol Ther202093173310.1007/s40120-020-00210-7750025132948978Search in Google Scholar